Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer DMD Gene Therapy Phase III Trial Stalled In US After FDA Questions On Potency Assays

May 07 2021

• By Jessica Merrill

FDA stop sign. Sarah Silbiger/Getty Images — • Source: Sarah Silbiger/Getty Images

Related Content

JAK-Inhibitor Review Delays Spur Talk Of US FDA Panel Meeting On Class Safety

Apr 08 2021

Bispecific Antibodies: US FDA May Require Comparison To Approved Monospecific Product

Apr 30 2019

Sarepta Sinks On Mixed DMD Gene Therapy Study

Jan 08 2021

Pfizer Says JAKs Have Their Place Despite Xeljanz Safety Issues

Feb 04 2021

Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific

Feb 22 2021

Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected

May 04 2021

ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma

Dec 09 2020

What Will JAK Inhibitor Safety Jitters Mean For Drug Sales?

Apr 07 2021

Solid Restarts DMD Gene Therapy Trial, With Encouraging Interim Data To Back It Up

Mar 16 2021

Related Companies

Pfizer Inc.

Sarepta Therapeutics, Inc.

Solid Biosciences Inc.

Regeneron Pharmaceuticals, Inc.

Johnson & Johnson

Additional Topics

United States Gene Therapy Drug Approval Standards Clinical Trials Research & Development Neurology BioPharmaceutical

More from Cell & Gene Therapies

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window